Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).
2016 ◽
Vol 34
(15_suppl)
◽
pp. 8559-8559
◽
2019 ◽
Vol 513
(4)
◽
pp. 1083-1091
◽
Keyword(s):
2019 ◽
Vol 26
(2)
◽
pp. 364-372
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Vol 23
(19)
◽
pp. 5711-5719
◽
Keyword(s):